• Explore /
  • Poster
  • / Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.

Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.

Abstract Poster

Authors

null

Eric Xueyu Chen

Princess Margaret Hospital, Toronto, ON, Canada

Eric Xueyu Chen , Petr Kavan , Mustapha Tehfe , Jeremy S. Kortmansky , Michael B. Sawyer , E. Gabriela Chiorean , Christopher Hanyoung Lieu , Blase N. Polite , Lucas Wong , Marwan Fakih , Kristen Renee Spencer , Jorge Chaves , Chenxiang Li , David Carpenter , Pierre Leconte , Richard D. Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03374254

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3573)

DOI

10.1200/JCO.2022.40.16_suppl.3573

Abstract #

3573

Poster Bd #

367

Abstract Disclosures

Similar Posters

First Author: Richard D. Kim

First Author: Makoto Nishio

First Author: Jiwon Lee

First Author: Meredith Pelster